Investment Research report

Align Technology, Inc.

NASDAQ:
algn
Previous Item
All Reports
Align Technology, Inc.
A Clear and Visible Short Case
Download Report
Align Technology, Inc.
Download Report 2
Align Technology, Inc.
Download Report 3
Align Technology, Inc.
Download Report 4
Align Technology, Inc.
Download Report 5
Align Technology, Inc.
Download Report 6
Align Technology, Inc.
Download Report 7

Research Overview

INDEX:
S&P 500
Sector:
Healthcare
Position:
Short
Date:
Apr 9, 2020

After conducting a forensic financial and accounting review, Spruce Point believes Align Technology (NASDAQ: ALGN), a global medical device company, is increasingly subject to the economics of clear aligners that are on the precipice of a radical shift. Based on our investigation, we estimate 40% to 55% downside risk, or $80 - $115 per share regardless of whether the deal is renegotiated or annulled completely.

The report highlights several key concerns with the company, including:

  • Evidence shows that third-party labs are turning aligners into commodities
  • We find improvements in technology which make in-house 3D printing a threat
  • We believe that widespread dissatisfaction with Align could accelerate customer losses
Downloads & More

Research Assets & Releases

Join The Mailing List

Spruce Point Alerts & Updates

See the other side of the Wall Street hype machine.